Goldman Sachs Group Inc Supernus Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 933,952 shares of SUPN stock, worth $30.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
933,952
Previous 899,637
3.81%
Holding current value
$30.7 Million
Previous $28.1 Million
20.4%
% of portfolio
0.01%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$341 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$202 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$159 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$94.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$86.3 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.76B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...